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Abstract
We expand Mendelian Randomization (MR) methodology to deal with randomly missing
data on either the exposure or the outcome variable, and furthermore with data from non-
independent individuals (eg components of a family). Our method rests on the Bayesian
MR framework proposed by Berzuini et al (2018), which we apply in a study of multiplex
Multiple Sclerosis (MS) Sardinian families to characterise the role of certain plasma proteins
in MS causation. The method is robust to presence of pleiotropic effects in an unknown
number of instruments, and is able to incorporate inter-individual kinship information.
Introduction of missing data allows us to overcome the bias introduced by the (reverse)
effect of treatment (in MS cases) on level of protein. From a substantive point of view, our
study results confirm recent suspicion that an increase in circulating IL12A and STAT4
protein levels does not cause an increase in MS risk, as originally believed, suggesting that
these two proteins may not be suitable drug targets for MS.
Introduction
Mendelian Randomization (MR) [21] [37] [10] [5] principles are well accepted in the
epidemiologic community. Once the appropriate assumptions are entertained, MR analysis
can be used to assess the effect of an ”exposure” variable on the medical outcome of interest,
even when the former is not experimentally controlled. In most MR studies so far, the
exposure is a late actor in the biological cascade, for example obesity [13]. Many such
studies exploit the wealth of data gathered from follow-up of a large cohort of (initially)
healthy population subjects.
This paper investigates methodological problems involved in the application of MR outside
the above described standard scenario. We investigate problems encountered when the
putative causal factor operates at a molecular (transcriptome or proteome) level (rather than
deep down the biological cascade), whether with the aim of dissecting a disease pathway or
discovering a new pharmacologic target. We also consider situations where the data are
collected from a small/isolated population, where one can reap the advantages of multiplex
family data analysis [9], and escape those biases in health research that are brought about
by excessive reliance on western-world biobanks. The isolated population considered in
the present paper belongs to a region of the Sardinian island, Italy.
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We also consider situations where biases may arise due to (i) the exposure in diseased
subjects being possibly affected by treatment, and (ii) random missingness of exposure
values.
In this paper we advocate a Bayesian approach to MR in the above scenarios. We have
constructed our proposed method out of the Bayesian MR framework described by Berzuini
and colleagues [4]. A Bayesian approach to MR appears to suit the study scenarios of
interest here. One reason being coherent handling of the uncertainty around the estimated
instrument-exposure associations, as a safeguard against the weak-instrument bias [6].
Another reason being freedom from asymptotic assumptions, as a safeguard against the
limited size of the sample and the limited number of instrumental variants associated with
a transcriptome/proteome-level exposure. And a final reason being coherent Bayesian
handling of missing exposure values, which are treated as additional parameters to be
estimated from the data, thereby avoiding the biases that affect two-sample frequentist
analysis. Also illustrated here is the ease of eleboration of the Bayesian model to deal with
inter-correlation of individuals within a family.
Our illustrative study addresses the question whether the concentration of certain inflamma-
tory proteins, IL12A in the first place, plays a causal role in the development of Multiple
Sclerosis (MS). Current opinion holds that an increase in the circulating level of some
of these proteins increases risk of MS. An MR analysis of our study data reverses this
opinion. In particular, our analysis discredits existing hopes that an decrease in IL12A
plasma concentration may reduce risk of the disease. This example also illustrates a change
with respect to the prevailing MR analysis ethos. In the context of mechanistic studies like
the one described in this paper, which sit at the frontier between epidemiology and biology,
emphasis is not on the statistical significance of estimates, as much as on the use of data
evidence to tip the balance between competing biological hypotheses. Fruitful interaction
between biologists and statisticians often takes place in this sort of grey area.
The computational engine of the proposed method is the same as in [4], being based on
recent developments in Markov chain Monte Carlo (MCMC) inference [25], which have
been implemented in the Stan probabilistic programming language [11].
The ”outcome” variable of our illustrative MR analysis is the MS disease indicator. MS
lends itself well to a MR study. This disease tends to become manifest early during repro-
ductive lifespan of most humans, throughout history, and is therefore likely to have a strong
genetic component. Genetic variants are therefore expected to act as good instruments
for the MR analysis, although their number will be inevitably smaller than in the case of
a high-level biomarker. The main scientific question in our study is whether the plasma
level of IL12A protein is causal with respect to development of MS. It is believed that
dysregulation of circulating proteins is a causal determinant in many pathologies, more
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directly so than genetic variants. Our analysis is further motivated by the importance of
proteins as natural drug targets.
Method
Sample Description
Our MS patients were ascertained through a case register established in 1995 in the province
of Nuoro, Sardinia, Italy. Cases were diagnosed according to Poser’s criteria [29]. Twenty
extended MS multiplex pedigrees were selected for the analysis, for a total of N = 936
individuals (98 cases and 838 unaffected relatives). A subset of the pedigree members
had complete data, consisting of the observed levels of the IL12A protein (the exposure),
the known disease indicator (the outcome variable), and the genotypes at all loci of the
Immunochip Illumina Infinium HD custom array (hereafter “Immunochip” for brevity),
designed for fine mapping of 184 established autoimmune loci [3]. . The remaining
individuals had complete data except for a missing value for the protein level.
Genotyping Data
The quality control-filtered set of genotyping data included 127134 Single Nucleotide
Polymorphisms (SNPs) across Immunochip [19]. We imposed a maximum correlation of
r2 = 0.20 between candidate instrumental SNPs within a 100 Kb window, by using the
indep-pairwise command of the PLINK package [30]. This yielded a total of 19121
candidate SNP instruments across Immunochip.
Protein Selection and Profiling
The proteins we chose for our illustrative study were IL12A, IL23A, IL4, STAT4, and
STAT6. Choice was made prior to considering the data, on the basis of Genome-Wide
Significant (GWS) association between MS and genetic variants located within (e.g. exonic,
intronic, in the UTR) or in the proximity (e.g. downstream, intergenic) of the protein-coding
gene [3], their involvemente in immune response and the availability in our sample of data.
Plasma profiles were analysed by using a bead-based antibody array format, consisting
of polyclonal Human Protein Atlas [26] antibodies immobilized onto microspheres in
suspension [32] [31] (see Supplementary Material for details).
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Selection of Instrumental Variants
Genetic variants with a significant marginal association (p < 5× 10−3) with the level of
the protein of interest and mutual r2 < 0.20 correlation were selected to act as instrumental
variables (IVs) in the first stage of our analysis. The liberal p < 5 × 10−3 threshold is
justified by the fine genotyping of candidate gene regions and by recent arguments [40] [41]
in favour of using sub-genome-wide-significance loci to strengthen biologically interesting
signals. It is also justified by the relative ability of our Bayesian MR method (when
compared with most frequentist approaches) to deal with the weak instrument bias, thanks
to the uncertainty of the estimated exposure coefficients being explicitly included in the
model.
Notation
Let, for example, the circulating level of protein IL12A act as the exposure in the analysis,
and be denoted as X . Let the symbol ΣX denote a regime indicator [17] [18], with ΣX = ∅
telling us that X is to be interpreted as the result of a passive observation (observational
regime), while ΣX = x tells us that the value if X is to be interpreted as fixed under a
hypothetical interventional regime to be equal to x. The outcome variable, Y , indicates
whether the individual has the disease (Y = 1) or not (Y = 0). We are interested in the
”causal effect” of X on Y , that is, in the way the distribution of Y changes when X is
first set by intervention to a reference value x0 and then forced to take the new value x1.
Throughout this paper we take this causal effect to be defined as the causal odds ratio
(COR):
COR =
P (Y = 1 | ΣX = x1)
P (Y = 1 | ΣX = x0)
1− P (Y = 1 | ΣX = x0)
1− P (Y = 1 | ΣX = x1) (1)
Presence of the unobserved confounders of the exposure-outcome relationship, denoted as
U , is the reason why we can’t generally measure the causal effect of X on Y by standard
regression of Y onX . A causally meaningful estimate of that effect can, under assumptions,
be obtained via MR. We shall model U as an individual-level scalar variable, more precisely,
a one-dimensional reduction of the unknown collection of confounders. MR requires
availability of a set of instrumental variables, or instruments, denoted as Z ≡ (Z1, . . . , ZJ),
which in a standard analysis will often correspond to the individual’s genotypes at a set
of SNP loci. Each of these genotypes we code as ”allele doses”, with values (0, 1, 2)
respectively indicating presence of zero, one and two copies of the ”alternative” allele at the
locus. For most individuals in the pedigree, we also have observed (i) maternal and paternal
genotypes at each instrumental locus and (ii) the levels of protein IL12A in the father and
in the mother. We further introduce an individual-level categorical variable, denoted as F ,
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which indicates the individual’s pedigree of membership, or family. Further notation will
be introduced in the next sections, as required.
Assumptions
We are going to describe conditions for validity of the method by using Dawid’s conditional
independence formalism [16], with the A⊥⊥B | C notation standing for “A is independent
of B given C, and A 6⊥⊥B, meaning “A is not independent of B ”. The conditions we are
going to introduce are essentially identical to those required by standard MR methods.
Each jth instrumental variable, Zj , must satisfy the confounder independence condition
Zj ⊥⊥U , stating that the instrument is unrelated to exposure-outcome confounders. This
condition is not directly testable. A further condition called exclusion-restriction requires
that Y ⊥⊥Zj | (X,U), that is, each jth instrument can be associated with response only via
the exposure. This condition cannot be directly tested. Exclusion-restriction is a desirable
condition, however, unlike the remaining conditions in this section, it is not required by
our method. Next comes the instrument relevance condition, Zj 6⊥⊥X , stating that no
instrument is independent of the exposure. We have also conditions involving the regime
indicator, ΣX . The confounder invariance condition, U ⊥⊥ΣX , requires that the distribution
of the confounders U be the same, whether or not we intervene on X , and regardless
of the value imposed on or observed in X . Next comes the interventional irrelevance
condition ΣX ⊥⊥Z, requiring that any intervention on X has no consequence on Z, and the
interventional modularity condition, ΣX ⊥⊥Y | (X,U), asserting that once we are told the
values of X and U , the distribution of Y no longer depends on the way the value of X has
arisen, whether observationally or through the intervention of interest.
All the conditions defined above, except for exclusion-restriction, are required by our
method.
Sometimes it is possible, and then helpful, to represent the qualitative structure of a
statistical model by a directed acyclic graph [22]. A stripped-down representation of the
class of MR models discussed in the present paper is shown in Figure 1. In this geaph, the
variable denoted by the symbol F is a family indicator, which we represent in the model
equations as a categorical factor with one level per family. Had we not allowed for the
presence of this indicator, we would have an unblocked path Z ← F → Y path (in a
d-separation terminology) corresponding to a spurious, exposure-unmediated, association
between instrument and outcome. This would violate the Confounder Independence
assumption, and consequently lead to a biased estimate of the causal effect. In situations
where the sample contains unrelated (in addition to related) individuals, the unrelateds may
be lumped into a single, notional, family.
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All the assumptions/conditions stated at the beginning of this section (except for exclusion-
restriction) can be read off the graph of Figure 1 by applying d-separation [20] or moraliza-
tion [22], with the following additional rules: (i) faithfulness [33] of the Z → X edges ),
meaning no instrument is independent of the exposure, and (ii) assigning a value x to ΣX
implies the simultaneous assignment of the same value to X , and (iii) assigning a value
x to ΣX implies that all arrows into X except for ΣX → X are severed. Because most
of the conditions introduced at the beginning of this section are not directly testable on
the basis of the data, the reader should be aware that graphs like the one shown in Figure
1 describe an assumed, ultimately uncertified, albeit plausible, state of affairs. We shall
assume throughout the paper that the above described conditions, bar exclusion-restriction,
are valid.
We conclude this section with a brief discussion of the exclusion-restriction assumption.
This assumption (which is not required by our method) does not allow an instrument to
exert an effect on Y other than that exerted though the mediating effect of X . In our graph
of Figure 1, this condition is violated by the ZJ → Y arrow. Because of this, the effect of
instrument ZJ on Y is said to be “pleiotropic ” according to Figure 1. In the context of our
application, pleiotropic effects may arise from two broad classes of mechanism. The first is
due to the variants used as instruments being in linkage disequilibrium (LD) with variants
of nearby genes. The second is due to the instrumental variant exerting a causal effect on
Y through a pathway independent of X . Although the former type of pleiotropy could,
in principle, be neutralized by conditioning on the variants in the region, except for the
instrumental variants, the latter cannot be directly tested from the data. It would therefore
be uncautious to perform MR by using a method that does not allow for general types of
pleiotropy. Our Bayesian approach deals with the problem by explicitly introducing the
unknown pleiotropic effects in the model, and by treating them as unknown parameters to
be estimated from the data.
Quantitative Specification of the Model
The graphical representation in Figure 1 is an elaboration of the model of Berzuini and
colleagues [4]. We note that in our representation the unobserved variable U is explicitly
included in the model, rather than integrated out. This choice does not affect the likelihood
function but will generally lead to different prior distributions. In the following equations
the continuous exposure variable, X , is implicitly assumed to be transformed to a zero
mean and unit standard deviation variable. In this preliminary version of the model, the
individuals are treated as conditionally independent given the family indicator, F . The
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Figure 1: Graphical representation of the model.
unobserved
U
Family
indicator
F
protein
level
X
affected by
disease?
Y
instrumental
genotypes
Z
ΣX
model allows for an effect of the family on both the exposure and the outcome, but assumes
that family and exposure do not interact in their effects on the outcome. The Reader
may wish to check that the graph (and the model equations) conform to the conditional
independence assumptions of the preceding section.
P (U) = N(0, 1),
P (X | Z1, . . . , ZJ , U, F ) = N(ν, σ2X),
ν =
J∑
j=1
αjZj + δXU +
M∑
f=1
IF=f γ
X
f ,
P (Y | X,Z1, . . . , ZJ , U, F ) = Bernoulli(pi),
logit(pi) = MVN(µ,Σ),
µ = ωY + θX +
J∑
j=1
βjZj + U +
M∑
f=1
IF=f γ
Y
f ,
where N(a, b) stands for a normal distribution with mean a and variance b, the symbol
α ≡ (α1, . . . , αJ) denotes the instrument-exposure associations, and β ≡ (β1, . . . , βJ) are
the pleiotropic effects. The notation IA stands for the indicator function, taking value 1 if
the logical condition A is true, and value 0 otherwise. The quantities γX ≡ (γX1 , . . . , γXM)
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and γY ≡ (γY1 , . . . , γYM) are vectors of unknown ”family effects” acting upon U . In our
analysis, we have imposed on these effects independent and mildly informative priors, with
greater spread than the prior for θ.
Unlike the model by Berzuini et al, the outcome variable Y here is distributed as a Bernoulli
random variable, as appropriate for a binary outcome. The causal effect of interest, denoted
as θ, represents the change in log-odds of probability of Y = 1 caused by an interventional
change of one standard deviation in X . Family information is incorporated by designating
a categorical variable F to indicate the individual’s family, with F ∈ (1, . . . ,M), and M
denoting the total number of families.
Recall that, in our study, some components of theX vector (protein level measurements) are
missing, which is not made explicit in the notation above. The Bayesian inference engine
identifies the missing components and treats them as unknown parameters, effectively
integrating them out to obtain the posterior distribution for the parameters of inferential
interest. Note that this way of dealing with missing data is more efficient than, say, imputing
each missing component of X on the basis of the individual’s observed Z values, thanks to
the fact that, in our method, the missing values are estimated by using information about
both X and Y .
As shown in [4] for the normal case, parameters (α, τX) are identified by the data, but
the remaining parameters, including the causal effect of interest, θ, are not. Berzuini and
colleagues deal with the problem by a combination of two devices. The first consists of
introducing the additional (untestable) assumption that each jth component of β is a priori
independent of the remaining parameters of the model, formally, P (βj | αj, τX) = P (βj).
This is called the Instrument Effects Orthogonality (IEO) condition. The second consists of
introducing a proper, scientifically plausible, prior for β, which makes inferences possible by
inducing on θ (and on further parameters of potential posterior interest) a proper posterior.
As concerns the prior component of our Bayesian model, we invite the Reader to consult [4].
Variations from [4] have been introduced. While still imposing on the pleiotropic effects β
a horseshoe prior [12], we are now using the enhanced version of this distribution proposed
by Piironen and Vehtari [27]. Also, we take θ – the causal effect of main inferential interest
– to have a Cauchy(0,2.5) prior, with the following justification. Because X has been
standardized to have mean 0 and unit standard deviation (SD), the mentioned prior for θ
states as unlikely that a one-SD change in protein level causes a change in risk of disease
exceeding 5 points on a logit scale, which corresponds to shifting a probability of disease
occurrence from, say, 0.01, to 0.5, or from 0.5 to 0.99. This is also in agreement with
current evidence on the effect of circulating proteins on disease [34].
Finally, we are now taking the instrument-exposure associations, α, to be independently
distributed according to a double-exponential distribution with mean 0 and unknown scale.
10
One merit of this prior is to shrink the small effects to zero, which reduces the weak
instrument bias, so that the model works with an adaptively selected subset of strong
instruments.
Introducing Kinship
The preceding model treats members of a pedigree as independent individuals, which
they are not. This will produce overconfident and biased estimates. We remedy this by
introducing in the model between-individual correlation in the form of the kinship matrix,
which can be derived by a standard algorithm from the structure of the pedigree. We are
currently working with a single, overarching, kinship matrix of size N ×N , where N is the
total number of individuals in the sample. This large matrix contains zeros corresponding
to pairs of individuals in different families. The method could be made computationally
more efficient by introducing family-specific matrices. Kinship information is introduced
in the model by replacing the previous specification for Y with:
P (Y | X,Z1, . . . , ZJ , U, F ) = Bernoulli(pi),
logit(pi) = MVN(µ,Σ),
µ = ωY + θX +
J∑
j=1
βjZj + U +
M∑
f=1
IF=f γ
Y
f ,
where Σ is the N × N kinship matrix, the notation MVN(a, b) stands for multivariate
normal distribution with vector mean a and variance-covariance matrix b.
Analysis Strategy and Results
Frequentist Analysis
We have separately studied the five proteins of interest via a standard battery of frequentist
MR algorithms, as offered by R package MendelianRandomization [42], as found
on http://cran.r-project.org.
For each individual protein, we proceeded by fitting a linear mixed-effects regression
model of the dependence of the circulating protein level, X , on each separate instrumental
SNP, adjusting for sex, with familial relatedness between individuals accounted for in the
model through the kinship matrix [28], by using the lmekin R function. Each of these
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regressions, ofX on Zj say, yields an estimated coefficient Φj and a corresponding standard
error. Only those disease-free individuals with a measured value of the X were involved
in these regressions. We then performed on the entire sample a logit-linear, sex-adjusted,
regression of Y on each jth SNP, and let the resulting effect estimate, on a log-odds ratio
scale, be denoted as Γj . The estimates of the {Φj} and of the {Γj} acted as an input to our
frequentist MR estimate of the COR effect of X on Y , and this analysis was replicated by
using each of the following frequentist MR methods: Inverse-Variance Weighted estimator
(IVW) [7] , the MR-Egger Regression estimator [8] and Weighted Median Estimator [7].
These methods, as provided by the mentioned MendelianRandomization R package,
are able to work from the Φj and Γj statistics to obtain the estimate of the causal effect of
interest, and assume the instruments to be independent.
The above approach acknowledges that exposure values in the diseased may have been
reverse-affected by treatment, and wisely discards them from the analysis, as if they were
missing. This, however, incurs bias due to using control data twice.
Results of these analyses are summarized below by plotting marginal effects of each
instrument on log-odds risk of disease against the corresponding effects on exposure (each
of the ”Egger plots” consists of a scatter diagram where each instrument is represented as
a dot, with horizontal coordinate {Φj} and vertical coirdinate {Γj} ), and, in addition, in
Table 1, by reporting the estimated causal effects, for each protein and algorithm, together
with their standard errors, 95% confidence intervals and P-values. Estimated intercepts
from the Egger methods are not reported.
Table 1: Results from a frequentist analysis of the causal effects of five proteins on susceptibility to
MS. The second column of the table indicates the MR algorithm.
PROTEIN IL4
Estimate Std
Error
95% CI P-value
1 Simple median 0.07 0.07 -0.06 0.21 0.28
2 Weighted median 0.09 0.07 -0.05 0.22 0.21
3 Penalized weighted median 0.08 0.07 -0.05 0.22 0.21
4 IVW 0.09 0.05 -0.00 0.18 0.05
5 Penalized IVW 0.08 0.05 -0.01 0.18 0.08
6 Robust IVW 0.08 0.04 -0.00 0.17 0.06
7 Penalized robust IVW 0.08 0.04 -0.00 0.17 0.06
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Table 1: (continued)
Mean Std
Error
95% CI P-value
8 MR-Egger 0.03 0.33 -0.62 0.67 0.94
9 Penalized MR-Egger 0.00 0.33 -0.64 0.65 0.99
10 Robust MR-Egger -0.02 0.27 -0.56 0.51 0.93
11 Penalized robust MR-Egger -0.03 0.27 -0.56 0.51 0.92
PROTEIN IL4
1 Simple median 0.07 0.07 -0.07 0.21 0.31
2 Weighted median 0.09 0.07 -0.05 0.22 0.21
3 Penalized weighted median 0.09 0.07 -0.05 0.22 0.21
4 IVW 0.09 0.05 0.00 0.19 0.05
5 Penalized IVW 0.09 0.05 -0.01 0.18 0.07
6 Robust IVW 0.09 0.04 -0.00 0.17 0.05
7 Penalized robust IVW 0.08 0.04 -0.00 0.17 0.05
8 MR-Egger 0.14 0.34 -0.53 0.81 0.68
9 Penalized MR-Egger 0.12 0.34 -0.55 0.79 0.73
10 Robust MR-Egger 0.09 0.25 -0.41 0.59 0.72
11 Penalized robust MR-Egger 0.09 0.26 -0.41 0.59 0.73
PROTEIN IL23A
1 Simple median -0.02 0.06 -0.14 0.09 0.67
2 Weighted median 0.04 0.06 -0.07 0.15 0.51
3 Penalized weighted median 0.04 0.06 -0.07 0.15 0.51
4 IVW 0.04 0.04 -0.04 0.12 0.31
5 Penalized IVW 0.04 0.04 -0.04 0.12 0.31
6 Robust IVW 0.03 0.05 -0.06 0.13 0.53
7 Penalized robust IVW 0.03 0.05 -0.06 0.13 0.53
8 MR-Egger 0.40 0.19 0.01 0.78 0.04
9 Penalized MR-Egger 0.40 0.19 0.01 0.78 0.04
10 Robust MR-Egger 0.43 0.27 -0.09 0.95 0.11
11 Penalized robust MR-Egger 0.43 0.27 -0.09 0.95 0.11
PROTEIN IL12A
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Table 1: (continued)
Mean Std
Error
95% CI P-value
1 Simple median -0.17 0.10 -0.36 0.02 0.08
2 Weighted median -0.12 0.09 -0.31 0.06 0.19
3 Penalized weighted median -0.13 0.09 -0.31 0.06 0.18
4 IVW -0.11 0.07 -0.24 0.02 0.09
5 Penalized IVW -0.11 0.07 -0.24 0.02 0.09
6 Robust IVW -0.12 0.06 -0.24 -0.00 0.05
7 Penalized robust IVW -0.12 0.06 -0.24 -0.00 0.05
8 MR-Egger -0.05 0.25 -0.53 0.44 0.85
9 Penalized MR-Egger -0.05 0.25 -0.53 0.44 0.85
10 Robust MR-Egger -0.04 0.22 -0.47 0.40 0.87
11 Penalized robust MR-Egger -0.04 0.22 -0.47 0.40 0.87
PROTEIN IL12A
1 Simple median -0.16 0.10 -0.35 0.03 0.09
2 Weighted median -0.12 0.09 -0.31 0.06 0.19
3 Penalized weighted median -0.13 0.09 -0.31 0.06 0.18
4 IVW -0.11 0.07 -0.24 0.02 0.09
5 Penalized IVW -0.11 0.07 -0.24 0.02 0.09
6 Robust IVW -0.12 0.06 -0.23 -0.00 0.05
7 Penalized robust IVW -0.12 0.06 -0.23 -0.00 0.05
8 MR-Egger -0.05 0.25 -0.53 0.44 0.85
9 Penalized MR-Egger -0.05 0.25 -0.53 0.44 0.85
10 Robust MR-Egger -0.04 0.22 -0.46 0.39 0.87
11 Penalized robust MR-Egger -0.04 0.22 -0.46 0.39 0.87
PROTEIN STAT4
1 Simple median -0.02 0.08 -0.17 0.13 0.80
2 Weighted median -0.07 0.07 -0.21 0.08 0.37
3 Penalized weighted median -0.07 0.07 -0.21 0.08 0.37
4 IVW -0.09 0.05 -0.19 0.01 0.08
5 Penalized IVW -0.09 0.05 -0.19 0.01 0.08
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Table 1: (continued)
Mean Std
Error
95% CI P-value
6 Robust IVW -0.07 0.06 -0.19 0.04 0.18
7 Penalized robust IVW -0.07 0.06 -0.19 0.04 0.18
8 MR-Egger -0.03 0.17 -0.37 0.31 0.87
9 Penalized MR-Egger -0.03 0.17 -0.37 0.31 0.87
10 Robust MR-Egger -0.10 0.14 -0.37 0.17 0.47
11 Penalized robust MR-Egger -0.10 0.14 -0.37 0.17 0.47
PROTEIN STAT6
1 Simple median -0.06 0.06 -0.18 0.05 0.25
2 Weighted median 0.02 0.05 -0.08 0.13 0.67
3 Penalized weighted median 0.03 0.05 -0.07 0.14 0.56
4 IVW -0.04 0.04 -0.11 0.03 0.22
5 Penalized IVW -0.04 0.04 -0.11 0.03 0.22
6 Robust IVW -0.04 0.04 -0.11 0.03 0.28
7 Penalized robust IVW -0.04 0.04 -0.11 0.03 0.28
8 MR-Egger 0.15 0.09 -0.03 0.34 0.10
9 Penalized MR-Egger 0.15 0.09 -0.03 0.34 0.10
10 Robust MR-Egger 0.16 0.07 0.02 0.29 0.03
11 Penalized robust MR-Egger 0.16 0.07 0.02 0.29 0.03
Bayesian Analysis
In our Bayesian analyses, we acknowledged the fact that the protein level values in MS
cases may be reverse-affected due to treatment by treating them as missing, and effectively
allowing them to be estimated by the MCMC algorithm. There were missing protein
values also in some disease-free subjects. The Bayesian method of dealing with missing X
values appears to be superior to simple replacement of those values with the corresponding
genotype-based predictions, in two respects. Firstly, within a Bayesian approach to MR,
the imputed X values reflect the information contained in individual’s genotypes but also,
in addition, they incorporate relevant information contained in the values of Y , via coherent
flow of the information all across the model. Secondly, within a Bayesian approach to the
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(a) Egger plots for proteins IL4 and IL23
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(b) Egger plots proteins IL12A and STAT4
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(c) Egger plots protein STAT6
problem, the uncertainty involved in the imputation of the missing X , and in particular
the uncertainty induced by the estimation of the α coefficients, is dealt with in a coherent
way. This is a crucial festure in the presence of weak instruments. In fact, during MCMC
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inference, the missing X values are re-imputed at each new iteration of the algorithm, so
as to reflect the uncertainty in all the parameters of the model. In each MCMC analysis,
we ran the Markov chain for 9000 iterations, and then used the sampled values generated
during the last 4500 iterations. Sampled values were used to approximate the posterior
distribution of the quantities of interest.
Reported in Table 2 are results from a Bayesian analysis of the causal effect of each protein
of interest on susceptibility to MS. The estimated (protein-specific) causal effects are
expressed as disease log-odds ratios and disease odds ratios for a standard deviation change
in level of circulating protein.
Table 2: Results from a Bayesian analysis of the causal effects of five proteins on susceptibility to
MS. The last seven columns of the table report percentile of the posterior distribution of the causal
effect.
PROTEIN IL4
Causal Exposure Log Odds Ratio -1.37 -0.77 -0.47 -0.15 0.25 0.74 1.61
Causal Exposure Odds Ratio 0.25 0.46 0.62 0.86 1.29 2.09 5.01
PROTEIN IL23A
Min 0.05 0.25 0.5 0.75 0.95 max
Causal Exposure Log Odds Ratio -1.24 -0.61 -0.29 -0.04 0.19 0.51 1.17
Causal Exposure Odds Ratio 0.29 0.54 0.75 0.96 1.20 1.66 3.22
PROTEIN IL12A
Causal Exposure Log Odds Ratio -5.74 -3.52 -2.65 -2.12 -1.46 -0.77 0.33
Causal Exposure Odds Ratio 0.00 0.03 0.07 0.12 0.23 0.46 1.39
PROTEIN IL12A
Causal Exposure Log Odds Ratio -5.55 -3.52 -2.48 -1.94 -1.41 -0.60 0.27
Causal Exposure Odds Ratio 0.00 0.03 0.08 0.14 0.25 0.55 1.30
PROTEIN STAT4
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Table 2: (continued)
Min 0.05 0.25 0.5 0.75 0.95 max
Causal Exposure Log Odds Ratio -2.04 -1.14 -0.78 -0.62 -0.50 -0.09 0.38
Causal Exposure Odds Ratio 0.13 0.32 0.46 0.54 0.61 0.91 1.46
PROTEIN STAT6
Causal Exposure Log Odds Ratio -1.05 -0.34 -0.25 0.04 0.24 0.46 1.08
Causal Exposure Odds Ratio 0.35 0.71 0.78 1.04 1.27 1.59 2.93
Interpretation of Results
Note that Table 1 contains two entries for IL4 and two entries for IL12. In both cases, the
first entry refers to an analysis with the full set of instruments, whereas the second refers
to an analysis where one outlier instrumental SNP (with an extreme negative value for its
effect on the outcome) was discarded from analysis. For all the five proteins under study,
the estimated values for the causal effect of interest (and in some proteins even their signs)
were not consistent across the array of frequentist MR algorithms. A discussion of this
issue is not within the scope of this paper. An overall tendency of the frequentist estimates
of the causal effect to have a negative sign for proteins IL12 and STAT4 is evident.
The Bayesian analysis highlights a potential causal effect of the circulating concentrations
of proteins IL12 and STAT4 on susceptibility to MS, corresponding to the 95% credible
intervals of these two estimated effects being entirely located in the negative real semi-
axis. We conclude that, under the appropriate assumptions, there is some evidence that
proteins IL12 and STAT4, but not the remaining ones, exert a causal effect on risk of
MS. The negative sign of the estimates in both cases suggests that an increase on plasma
concentration of the protein tends to reduce the risk of MS.
Discussion
Methodological
In this paper, the Bayesian MR framework of Berzuini and colleagues [4] has been ex-
tended in response to difficulties encountered in the study of an isolated and genetically
homogeneous subpopulation of Sardinia with extremely high incidence of MS. Among the
difficulties we mention the (inevitably) limited sample size, the strong family relationships
between sampke individuals, and the presence of missing exposure values. The missing
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values arose from the need to acknowledge that exposure values in the diseased may have
been reverse-affected by treatment, and from our consequent decision to treat them as
missing. Further difficulties arose from the peculiar choice of exposure variable – the
concentration of a protein – which operates at the beginning of the biological cascade,
thereby making it hard to gather strong instrumental information. Instrumental weakness
does, in turn, introduce vulnerability to confounding, which is only partly remedied by use
of pedigree data (see later comments).
The above described, problematic, situation is naturally and conveniently tackled via
a Bayesian approach to MR. And for a number of reasons. The first reason being a
probabilistically coherent handling of missing data. The second being coherent handling of
parameter estimation uncertainty, especially in relation to estimation of weak instrument-
exposure associations. The third reason being full exploitation of data information. The
fourth being ease of model extension, illustrated in our study by incorporation of between-
individual outcome correlation and family effects.The fifth being freedom from large
sample asymptotic approximations, which is an advantage in the study of small populations,
considering also that introduction of kinship information in the model will reduce the
number of ”effective” individuals. Failure to account for this phenomenon, and for family
effect, may lead to overoptimistic conclusions about the causal effect of interest.
This paper illustrates the extension of the Bayesian MR framework to deal with family
data. Family data analysis is more robust to population stratification and heterogeneity
than analysis of unrelateds, and promises to disentangle inheritable from environmental
effects. A potentially fruitful idea is to collect data from unrelated individuals and then to
collect further data from the parents of those individuals, for a joint analysis of the two
data sources. Such a joint analysis can be performed via our proposed approach by treating
parent-child triads as ”families”. Or one could use information from previous analyses
of unrelateds in order to shape informative priors for an analysis of pedigree data along
our proposed lines. Pedigree analysis might prove an invaluable tool for studying disease
mechanism peculiarities of small, possibly native and isolated, populations. We are, in
particular, thinking of small populations characterized by maverick disease patterns, that
suffer from inadequate attention from the medical research community, perhaps outside the
western ”white” world.
Substantive
MS is an immune-mediated demyelinating disease, showing CNS lymphocyte infiltration,
production of pro-inflammatory cytokines, and inappropriate activation of Th1, Th17, B,
and natural killer (NK) cells [38]. Genome-wide association studies discovered, among
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others, MS-associated risk alleles in the IL12/STAT4 and IL23/STAT3 pathways implicated
in the differentiation of Th1, Th2, and Th17 cells [14]. These pathways are profoundly
interlaced, considering both the repertoire of protein subunits taking part in the formation
of cytokines and of their receptors, as well as the involvement of downstream transcription
factors that result activated (i.e., signal transducer and activator of transcription, STAT,
proteins). In particular, the Interleukin 12 (IL12) family of cytokines is composed of four
different members (IL12, IL23, IL27, IL35), and each member is a heterodimer composed
of two subunits, an α-subunit (p35, p19, or p28, encoded by the IL12A, IL23A, and IL27A
gene, respectively) and a β-subunit (p40 or Ebi3, encoded by the IL12B and EBI3 gene,
respectively) [36]. The three α subunits are structurally related, and each can pair with
either of the structurally homologous β subunits. So that, pairing of the α-subunits, p35 or
p19, with p40, generates the two pro-inflammatory IL12 and IL23 cytokines, respectively;
conversely, the two immune-suppressive members of the family, i.e. IL27 and IL35, derives
from the pairing of p28 or p35 with Ebi31 [36]. Figure 3 summarizes the composition of the
IL12 family, and recapitulates the major links present among cytokines, immunologically
relevant cells, and MS.
In our work, we found altered levels of the IL12/STAT4 axis. IL12 is produced mainly
by antigen presenting cells (APCs, e.g. dendritic cells or macrophages). It acts as an
immunological playmaker by inducing: i) Th1 cell differentiation from CD4+ naive T cells;
ii) interferon gamma (IFN-γ) production; and iii) tumor necrosis factor-alpha (TNF-α)
production from T and NK cells [1]. The hypothesised causal effect of IL12 on MS risk
might be mediated by higher levels of expression of this cytokine, with the subsequent
IL12-induced production of IFN-α. Indeed, IFN-γ is a major cytokine found in MS lesions,
and it has been found that its levels are greatly increased during MS activity [23]. A very
recent meta-analysis, performed on a total of 226 studies with 13,526 MS patients, seems
to confirm that increased levels of IL12 are present in blood and/or cerebrospinal fluid of
MS patients [2]. On the contrary, we found that an increase in plasma concentration of the
IL12 protein tends to reduce the risk of MS. In our opinion, this is not surprisingly for a
number of reasons.
First, in the above mentioned meta-analysis, increased levels of IL12 were reported as
measured either considering the p40 (IL12B) subunit alone, or the p70 (IL12A+IL12B)
heterodimeric protein, whereas our study points to decreased levels in MS of the p35 subunit
(IL12A) only. This is not trivial, considering that the p35 subunit is part not only of the IL12
complex, but also of the IL35 cytokine, and, similarly, p40 takes part to the composition
of both IL12 and IL23. But while IL12 and IL23 are pro-inflammatory cytokines, IL35 is
inhibitory, so that their overall balance is crucial for the modulation of immune function.
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Second, it has been recently demonstrated that IL12-p35 induces expansion of IL10 and
IL35-expressing regulatory B cells, thus ameliorating autoimmune disease [39] [15].
Third, also genetics can help us in differentiating the roles for p35 and p40 (rather than IL12
“as a whole”). In this frame, an interesting review by [35] clearly showed that, on the basis on
association studies between autoimmune diseases with the various IL12 regions, two major
clusters of diseases can be distinguished: the first one including Crohn’s disease, ulcerative
colitis, psoriasis and psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis;
these diseases show preferential associations with the IL12B gene region, indicating a
pivotal role for the Th17/Th1 pathways. Instead, the second cluster encompasses primary
biliary cirrhosis, celiac disease, Graves disease, and MS; these conditions show significant
associations with polymorphisms in the IL12A gene region, thus indicating a specific role
for p35. Finally, our data, together with those mentioned above and reported by [15], might
reconcile with the notion that IL12/IL23 antibody therapy failed to be effective in MS [24].
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Figure 3: IL12 family cytokines as a putative immunological link between IL12A and MS.
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